Koji Sasaki

Has grant

Assistant Professor

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Koji Sasaki is an Assistant Professor at The University of Texas MD Anderson Cancer Center, USA. His research focuses on acute myeloid leukemia, myelodysplastic syndromes, and the genomic landscape of leukemias, particularly in relation to treatment outcomes. Recent articles discuss the impact of molecular prognostic scoring systems and innovative treatment regimens for various hematological malignancies.

Recent Grants

Grant: Close

Clinical Application of Artificial Intelligence in Patients with Acute Leukemia

Open Date: 2018-06-01

Close Date:

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (18)

Hussein A. Abbas

The University of Texas MD Anderson Cancer Center

UNITED STATES

Koji Sasaki

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML

Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phase

Mini-Hyper-CVD plus Venetoclax and Navitoclax for Relapsed/Refractory Acute Lymphoblastic Leukemia

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML

Management of Chronic Myeloid Leukemia During Pregnancy: Review of Evidence and Treatment Algorithm

MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia

Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome

Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy

Treatment of RAS-associated leukoproliferative disease (RALD) and Rosai-Dorfman disease in a patient with KRAS mutation

Mortality and relapse dynamics in AML after three years of complete remission

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre‐ and post‐ponatinib era

Performance of IPSS‐M in patients with myelodysplastic syndrome after hypomethylating agent failure

Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants

Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation

Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia

The role of therapy in the outcome of patients with myelofibrosis

Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma

Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid Leukemia

Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results

Myeloid lineage switch in <i>KMT2A-</i>rearranged acute lymphoblastic leukemia treated with lymphoid lineage-directed therapies.

Collaborators (18)

Hussein A. Abbas

Amber Gibson

Jayastu Senapati

Alex Bataller Torralba

Ghayas C. Issa

Rashmi Kanagal Shamanna

Fadi Haddad

Sanam Loghavi

Samanta Catueno

Tareq Abuasab

Nicholas J. Short

Patrick Reville

Michael Roth

Jennifer Croden

Elias J. Jabbour

Courtney D. DiNardo

Musa Yilmaz

Naval G. Daver

Make your next move.